Efficacy of Granulocyte Colony Stimulating Factor (GCSF) In Patients With Dystrophic Epidermolysis Bullosa
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
This is a feasibility study to see if Granulocyte Colony Stimulating Factor (GCSF) is
effective as a treatment of Dystrophic Epidermolysis Bullosa (EB). Patients will receive one
course of treatment with the study drug. The course will be 7 days in length. After receiving
GCSF, patients will be followed at 7 and 30 days following the discontinuation of the drug.
Thirty day follow up can be done via telephone communication with the patient or family.
Phase:
Phase 2
Details
Lead Sponsor:
Vanderbilt University Vanderbilt University Medical Center